# DESCRIPTION

## STATEMENT OF U.S. FEDERALLY FUNDED RESEARCH

- disclose government funding

## BACKGROUND

- introduce epigenetics and XCI

## SUMMARY OF THE DISCLOSURE

- introduce XCI mechanism
- describe gene expression on inactive X chromosome
- discuss escape from XCI
- highlight importance of DNA methylation in XCI
- introduce CRISPR system for targeted epigenetic modification
- provide overview of disclosure

## DETAILED DESCRIPTION

- establish context and definitions
- outline conventions and practices

### Definitions

- define singular and plural forms
- define measurable value variations
- define acceptable, effective, and sufficient terms
- define various technical terms
- define endonuclease variants
- define biological equivalents
- define expression and expression levels
- define functional molecules
- define guide polynucleotides
- define homology and hybridization
- define isolated molecules and biological terms
- define key terms
- describe biological concepts
- explain gene editing terminology
- define cell types and their characteristics
- describe cell differentiation and lineage
- provide additional definitions for stem cells and related concepts
- define pluripotent cell
- define vector
- describe biological equivalents
- describe pharmaceutically acceptable salts
- introduce gene editing systems
- describe dCas9-TET1 fusion protein
- describe targeted demethylation
- describe dCas9-TET1CD fusion protein
- describe transcriptional activator
- describe gene activation
- define gene editing system
- describe vector systems
- provide kit and pharmaceutical composition
- describe host cell
- define sgRNA vectors
- describe dCas9-TET1CD fusion protein
- introduce host cells
- describe gene editing systems
- outline vector construction
- describe sgRNA expression
- detail host cell engineering
- describe dual expression of dCas9-VP64 and dCas9-TET1CD
- summarize vector encoding multiple sgRNAs
- define host cell
- describe sgRNA and dCas9-TET1CD fusion protein
- describe pharmaceutical composition
- describe host cell expressing multiple sgRNAs
- describe host cell expressing dCas9 protein fused to transcriptional activator
- describe vector composition
- describe cloning of nucleotide molecules into vectors
- describe host cell engineered to express vector encoding sgRNA
- define cell assay systems
- describe therapeutic and diagnostic methods
- motivate gene editing system
- describe method for increasing CDKL5 gene expression
- provide pharmaceutical composition and administration methods
- describe kits for gene editing system

### EXAMPLES

- introduce examples of the present technology
- describe material and methods for cloning of sgRNAs
- outline transient transfection experiments
- detail integrative XCI status analysis of CDKL5
- describe lentivirus production and purification
- outline targeted X-reactivation analysis
- detail targeted DNA demethylation analysis
- describe chromatin immunoprecipitation and ChIP-qPCR
- outline whole-genome methylation analysis by Infinium MethylationEPIC array
- introduce CDKL5 gene reprogramming
- motivate dCas9 effector domains
- describe experimental design
- summarize CDKL5 expression results
- analyze X chromosome reactivation
- investigate DNA methylation reduction
- examine histone mark depletion
- evaluate global promoter hypomethylation

### Experimental Discussion

- demonstrate epigenetic barrier removal
- show programmable transcription using transactivator
- identify dCas9 binding effect on gene reactivation
- demonstrate targeted reduction of CpG methylation
- show synergistic effect of TET1CD and VP64 on gene expression

## EQUIVALENTS

- define scope of invention
- clarify limitations and equivalents

